Avicanna Announces Closing of Non-brokered Private Placement
18 avr. 2024 17h00 HE
|
Avicanna Inc.
TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing,...
Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
10 avr. 2024 08h37 HE
|
Avicanna Inc.
TORONTO, April 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing,...
Avicanna Reports Full Year 2023 Audited Financial Results
02 avr. 2024 07h30 HE
|
Avicanna Inc.
$16.8M in Revenue, representing an increase of 314% from 2022$6.7M Consolidated gross Profit, representing an increase of 500% from 2022 TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Avicanna...
Avicanna anuncia el lanzamiento en Canadá de una formulación de su propiedad con un 10% de CBD (sin THC)
28 mars 2024 07h30 HE
|
Avicanna Inc.
La formulación oral con un 10% de CBD (sin THC) se comercializa como RHO Phyto Micro Drop 100 en Canadá. RHO Phyto Micro Drop 100 está disponible exclusivamente en MyMedi.ca. TORONTO, March 28,...
Avicanna Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation
27 mars 2024 08h02 HE
|
Avicanna Inc.
The 10% CBD (THC free) proprietary oral formulation branded as RHO Phyto Micro Drop 100 in Canada RHO Phyto Micro Drop 100 is available exclusively at MyMedi.ca. TORONTO, March 27, 2024 (GLOBE...
Avicanna To Hold Full Year 2023 Earnings Conference Call
26 mars 2024 07h30 HE
|
Avicanna Inc.
TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna obtiene su primer registro de medicamento para indicación específica con Trunerox™
29 févr. 2024 08h00 HE
|
Avicanna Inc.
TORONTO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" o la "Empresa) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) una empresa biofarmacéutica centrada en el desarrollo, fabricación y...
Avicanna Hosts Symposium on Cannabinoid-based Medicine
29 févr. 2024 07h30 HE
|
Avicanna Inc.
TORONTO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Announces New Research Collaboration with a Multi-national European-based Pharmaceutical Company
15 févr. 2024 07h30 HE
|
Avicanna Inc.
TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Obtains Its First Indication-Specific Drug Registration with Trunerox™
13 févr. 2024 07h30 HE
|
Avicanna Inc.
TORONTO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...